MoonLake Immunotherapeutics (MLTX)

MLTX Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-210.5	-118.94	-36.01	-49.97	-64.37
Depreciation & Amortization	2.23	1.38	0.37	0.16	0.01
Asset Writedown & Restructuring Costs	-	-	-	-	5.82
Stock-Based Compensation	11.24	7.28	7.11	9.65	10.86
Other Operating Activities	-4.63	-2.53	-8.03	-14.16	0.09
Change in Accounts Receivable	-1.61	-1.79	-0.84	-0.07	-0.18
Change in Accounts Payable	14.57	7.15	1.58	-1.31	1.88
Change in Other Net Operating Assets	3.01	-9.15	-6.96	-0.2	3.68
Operating Cash Flow	-185.69	-116.59	-42.78	-55.89	-42.21
Capital Expenditures	-0.21	-0.52	-0.28	-0.02	-0.06
Investment in Securities	85.78	-205.08	-24.9	-32.32	-
Investing Cash Flow	85.57	-205.6	-25.18	-32.34	-0.06
Total Debt Issued	73.02	-	-	-	18
Short-Term Debt Repaid	-	-	-	-15	-
Total Debt Repaid	-	-	-	-15	-
Net Debt Issued (Repaid)	73.02	-	-	-15	18
Issuance of Common Stock	0.73	52.78	482.45	0.05	0.13
Repurchase of Common Stock	-0	-0	-	-	-0.01
Other Financing Activities	-0	-1.47	-2.75	134.65	-
Financing Cash Flow	73.75	51.31	479.7	119.69	51.92
Foreign Exchange Rate Adjustments	1.44	0.13	-0.08	0.01	0
Net Cash Flow	-24.92	-270.74	411.66	31.47	9.65
Free Cash Flow	-185.9	-117.11	-43.06	-55.91	-42.27
Free Cash Flow Per Share	-2.94	-1.86	-0.88	-1.90	-5.39
Cash Income Tax Paid	0.21	0.15	0.04	0	-
Levered Free Cash Flow	-117.38	-92.06	-24.14	-32.23	-
Unlevered Free Cash Flow	-114.1	-92.06	-24.14	-32.23	-
Change in Working Capital	15.97	-3.78	-6.22	-1.58	5.38

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q